基本情報
- CAS
50-04-4- 標準SMILES
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C- InChIKey
ITRJWOMZKQRYTA-RFZYENFJSA-N- 分子式
- C23H30O6
- 平均分子量
- 402.5 g/mol
- 単同位体質量
- 402.20423867
名称と識別子
- 優先名称
- Cortisone Acetate
- IUPAC
- [2-[(8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3,11-dioxo-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
- 現地名
- 酢酸コルチゾン
- 英語名
- Cortisone acetate
- 分子式
- C23H30O6
- 分子量
- 402.48
名称と別名
CORTISONE ACETATE50-04-4Cortisone 21-acetateCortone acetateCortisylCortelanCortistabPregn-4-ene-3,11,20-trione, 21-(acetyloxy)-17-hydroxy-Cortisone, 21-acetateCortisone aceticumDTXSID0022858NSC-49420
名称をさらに表示
酢酸コルチゾン21-(アセチルオキシ)-17-ヒドロキシプレグナ-4-エン-3,11,20-トリオンイリソンアセタートコルトンアセタートアドレソンコルチシルインコルチンコートンリコルテックスコルテランアルトリオナコルチゾンアセタートコルチソンアセタート化合物Eアセタート21-アセトキシ-17α-ヒドロキシプレグナ-4-エン-3,11,20-トリオンコルチシルアルトリオナコルリンビオコルトアセタート21-アセトキシ-17-ヒドロキシプレグナ-4-エン-3,11,20-トリオンコルチソン21-アセタート2-((8S,9S,10R,13S,14S,17R)-17-hydroxy-10,13-diMethyl-3,11-dioxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetateartrionaricortex
物性
構造計算による物性
- XLogP
- 2.1
- 極性表面積
- 97.7 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 6
- 回転可能結合数
- 4
- 重原子数
- 29
- 形式電荷
- 0
- 複雑度
- 827
実験および物理化学的性質
LogP
2.1
2.10
Solubility
20
2.78e-02 g/L
Melting Point
227-229
222 °C
Physical DescriptionSolid
Collision Cross Section196.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 237 · 237-240 °C(lit.)
- 比旋光度
- 25 · D25 +164° (c = 0.5 in acetone); D25 +208 to +217° (dioxane)
- 沸点
- 577.3 · 577.3±50.0 °C(Predicted)
- 比重(密度)
- 1.26 · 1.26±0.1 g/cm3(Predicted)
- 屈折率
- 212 ° · 212 ° (C=1, MeOH)
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- 水にほとんど溶けず、ジクロロメタンに溶けやすく、ジオキサンに溶けやすく、アセトンに溶けにくく、エタノール (96%) およびメタノールに溶けにくい。
- 外見
- Solid
- 酸解離定数(Pka)
- 12.32 · 12.32±0.60(Predicted)
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H312 (73.9%): Harmful in contact with skin [Warning Acute toxicity, dermal]；H332 (73.9%): Harmful if inhaled [Warning Acute toxicity, inhalation]；H361 (87%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P261, P271, P280, P302+P352, P304+P340, P317, P318, P321, P362+P364, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 23 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
危険有害性情報
Regulatory Information
Status: Active Update: 14-01-2022 https://echa.europa.eu/registration-dossier/-/registered-dossier/21329
Cortisone acetate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - Pregn-4-ene-3,11,20-trione, 21-(acetyloxy)-17-hydroxy-: Environment tier I assessment；IMAP assessments - Pregn-4-ene-3,11,20-trione, 21-(acetyloxy)-17-hydroxy-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (73.9%)；Acute Tox. 4 (73.9%)；Repr. 2 (87%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Cortisone acetate
化学と産業
薬理情報
Protein BindingCorticosteroids are generally bound to corticosteroid binding globulin and serum albumin in plasma.
Pharmacodynamics
Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. The duration of action is moderate as it is generally given once daily. Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.
Mechanism of Action
The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.
FDA Pharmacological Classification
CORTISONE ACETATE
Corticosteroid Hormone Receptor Agonists [MoA]; Corticosteroid [EPC]
MeSH Pharmacological ClassificationSubstances that reduce or suppress INFLAMMATION.
Absorption, Distribution and Excretion
Corticosteroids are eliminated predominantly in the urine.
Data regarding the clearance of cortisone acetate is not readily available.
関連反応
1 件
化合物ノート
読み込み中…